EyePoint Pharmaceuticals (EYPT) Tops Q1 EPS by 11c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q1 EPS of ($0.56), $0.11 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $7.39 million versus the consensus estimate of $7.91 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight